Trial record 22 of 360 for:    "Muscular Dystrophies"

Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02667483
Recruitment Status : Active, not recruiting
First Posted : January 29, 2016
Last Update Posted : January 4, 2018
Orphan Disease Treatment Institute Co., Ltd.
Information provided by (Responsible Party):
Daiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd. )

Brief Summary:
This is a phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping and to determine the dosage for subsequent studies.

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Drug: DS-5141b Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Actual Study Start Date : October 2015
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : April 2018

Arm Intervention/treatment
Experimental: DS-5141b

DS-5141b, Subcutaneous injection

Part 1: DS-5141b will be injected subcutaneously once a week for 2 weeks at the following dose levels. Dose escalation will be performed. DS-5141b will be administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.

  • Level 1: 0.1 mg/kg
  • Level 2: 0.5 mg/kg
  • Level 3: 2.0 mg/kg
  • Level 4: 6.0 mg/kg

Part 2: Two doses of DS-5141b will be selected based on the results obtained in Part 1. Each selected dose will be administered subcutaneously once a week for 12 weeks.

Drug: DS-5141b
DS-5141b, Subcutaneous injection

Primary Outcome Measures :
  1. Number of participants with treatment-emergent adverse events (TEAEs) by the end of the trial [ Time Frame: within 12 weeks ]
    TEAEs are adverse events (including clinically significant laboratory values) temporally associated with use of DS-5141b, whether or not attributable to the product.

  2. Maximum concentration (Cmax) of DS-5141b [ Time Frame: Week 12 ]
  3. Area under the curve (AUC) for DS-5141b [ Time Frame: Week 12 ]
  4. Time to maximum concentration (Tmax) of DS-5141b [ Time Frame: Week 12 ]
  5. Half-life (T1/2) of DS-5141b [ Time Frame: Week 12 ]
  6. Dystrophin protein expression in muscle tissue [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Production of exon 45-skipped dystrophin mRNA in muscle tissue [ Time Frame: Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 10 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmation of out-of-frame deletion(s) that could be corrected by dystrophin gene exon 45 skipping.
  • Intact muscles of adequate quality for biopsy to allow evaluation of the efficacy of the study drug.
  • Boys aged from 5 years to <11 years.
  • Patients able to walk at least 325 meters in the 6-minutes walk test.
  • Glucocorticoid-naive patients, or patients who have used glucocorticoids for at least 6 months prior to enrollment in this study with no dose changes for at least 3 months prior to enrollment.

Exclusion Criteria:

  • A genetic mutation that can not be expected the expression of dystrophin protein by dystrophin gene exon 45 skipping.
  • A concurrent illness other than DMD that can cause muscle weakness and/or impairment of motor function.
  • Current or history of severe disorder.
  • Left ventricular ejection fraction (LEVF) <55%.
  • Corrected QT interval (QTc) >0.45 sec.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02667483

Kobe University Hospital
Hyogo, Kobe-shi, Japan, 650-0017
National Center of Neurology and Psychiatry
Tokyo, Kodaira-shi, Japan, 187-8551
Sponsors and Collaborators
Daiichi Sankyo Co., Ltd.
Orphan Disease Treatment Institute Co., Ltd.
Study Director: Global Clinical Leader Daiichi Sankyo, Inc.

Responsible Party: Daiichi Sankyo Co., Ltd. Identifier: NCT02667483     History of Changes
Other Study ID Numbers: DS5141-A-J101
First Posted: January 29, 2016    Key Record Dates
Last Update Posted: January 4, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Daiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd. ):
Duchenne muscular dystrophy
Oligonucleotides, Antisense
Exon skipping

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked